MarginsXMarginsX
Home › Markets › Health Care › TRVI

Trevi Therapeutics Inc. (TRVI)

TRVI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$13.29
-2.64% on the day
Market cap
$1.9B
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerTRVI on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2019
SEC CIK0001563880
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
5.4 months
$27.8M cash at September 30, 2026
Share count, 1 year
+11.2%
2025-10-31 to 2026-10-31 · +123.2% over 3 years
Going-concern doubt
No
10-Q filed November 9, 2026
Insider net buying, 12 months
-$594K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-09
Cash and burn$27.8M cash; operating cash flow -$15.4M a quarter.Report 2026-09-30
Shares outstanding142,559,400 (2026-10-31); 128,230,134 a year earlier; 63,857,622 three years earlier.Cover page 2026-10-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-04-17
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, New York, New York, United StatesPCAOB Form AP 2026-03-27
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $594K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$21.5M-$19.7M$27.8MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2026
2026-06-30
Not filed-$17.8M-$17.4M$54.3MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2026
2026-03-31
Not filed-$13.2M-$16.7M$19.4MNo debt tagsNeeds four quarters10-Q 2026-05-05
Q4 2025
2025-12-31
Not filed-$8.3M-$7.6M$18.9MNo debt tagsNeeds four quarters10-K 2026-03-17
Q3 2025
2025-09-30
Not filed-$11.8M-$10.9M$56.9MNo debt tagsNeeds four quarters10-Q 2026-11-09
Q2 2025
2025-06-30
Not filed-$12.3M-$10.1M$117.1MNo debt tagsNeeds four quarters10-Q 2026-08-06
Q1 2025
2025-03-31
Not filed-$10.3M-$13.5M$19.4MNo debt tagsNeeds four quarters10-Q 2026-05-05
Q4 2024
2024-12-31
Not filed-$11.4M-$9.6M$34.1MNo debt tagsNeeds four quarters10-K 2026-03-17

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-04-17
Latest annual report10-K2026-03-17
Latest quarterly / interim10-Q2026-11-09
Latest current report8-K2026-11-09
Latest proxyDEF 14A2026-04-21

Source: SEC EDGAR submissions feed, 540 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-4.7%
1 month+11.1%
3 months-24.8%
Year to date+9.0%
1 year+19.1%
From 52-week high-30.0%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ZBIOZenas BioPharma Inc.$27.93-0.29%$1.9B
MRVIMaravai LifeSciences Holdings Inc.$7.40-1.86%$1.9B
HRMYHarmony Biosciences Holdings Inc.$32.96-2.37%$1.9B
ETONEton Pharmaceuticals Inc.$63.88-0.08%$1.8B
VERAVera Therapeutics Inc.$26.97-4.02%$1.9B
TRAXFirst Tracks Biotherapeutics Inc. Ordinary Shares$46.56-1.15%$2.0B
ZYMEZymeworks Inc.$26.45+0.80%$1.8B
SEPNSepterna Inc.$41.67-2.18%$2.0B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier